PH12021552788A1 - Stabilized formulations containing anti-angptl3 antibodies - Google Patents

Stabilized formulations containing anti-angptl3 antibodies

Info

Publication number
PH12021552788A1
PH12021552788A1 PH1/2021/552788A PH12021552788A PH12021552788A1 PH 12021552788 A1 PH12021552788 A1 PH 12021552788A1 PH 12021552788 A PH12021552788 A PH 12021552788A PH 12021552788 A1 PH12021552788 A1 PH 12021552788A1
Authority
PH
Philippines
Prior art keywords
angptl3
antibody
formulations containing
containing anti
stabilized formulations
Prior art date
Application number
PH1/2021/552788A
Other languages
English (en)
Inventor
Dingjiang Liu
Andria Skinner
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PH12021552788A1 publication Critical patent/PH12021552788A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PH1/2021/552788A 2019-05-24 2020-05-24 Stabilized formulations containing anti-angptl3 antibodies PH12021552788A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962852643P 2019-05-24 2019-05-24
PCT/US2020/034438 WO2020243031A1 (en) 2019-05-24 2020-05-24 Stabilized formulations containing anti-angptl3 antibodies

Publications (1)

Publication Number Publication Date
PH12021552788A1 true PH12021552788A1 (en) 2022-09-28

Family

ID=72179136

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552788A PH12021552788A1 (en) 2019-05-24 2020-05-24 Stabilized formulations containing anti-angptl3 antibodies

Country Status (16)

Country Link
US (1) US12559551B2 (https=)
EP (1) EP3976647A1 (https=)
JP (1) JP7783051B2 (https=)
KR (1) KR20220011727A (https=)
AU (1) AU2020282956A1 (https=)
BR (1) BR112021023501A2 (https=)
CA (1) CA3139333A1 (https=)
CL (1) CL2021003026A1 (https=)
CO (1) CO2021016183A2 (https=)
EA (1) EA202193240A1 (https=)
IL (1) IL288153A (https=)
MA (1) MA56049A (https=)
MX (1) MX2021014332A (https=)
PH (1) PH12021552788A1 (https=)
SG (1) SG11202112256SA (https=)
WO (1) WO2020243031A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
IL308643B2 (en) 2017-05-05 2025-02-01 Regeneron Pharma Auto-injector
JP2024509937A (ja) * 2021-03-09 2024-03-05 ジーアイ・イノベイション・インコーポレイテッド Ｉｇｅ ｆｃ受容体のアルファサブユニットの細胞外ドメインを含む融合タンパク質の製剤
EP4375298A4 (en) * 2021-07-21 2025-02-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
EP4453210A1 (en) 2021-12-22 2024-10-30 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors
IL316249A (en) 2022-05-02 2024-12-01 Novo Nordisk As Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
EP4615974A1 (en) 2022-11-10 2025-09-17 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
EP1151092B1 (en) 1999-02-12 2008-12-31 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions with afabp antisens nucleic acids
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
NZ527408A (en) 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
EP1451578B1 (en) 2001-11-16 2013-08-21 Genentech, Inc. Use of angptl3 antagonists for the treatment of liver diseases
EP2322200A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2398476B1 (en) 2009-02-23 2018-02-07 Nanorx, Inc. Policosanol nanoparticles
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
JP5602850B2 (ja) 2009-07-14 2014-10-08 ザ スクリプス リサーチ インスティテュート 間葉幹細胞分化
CN102753186B (zh) 2010-01-08 2016-09-14 Isis制药公司 血管生成素样3表达的调节
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
EP2723758B1 (en) 2011-06-21 2018-06-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
US20160002315A1 (en) 2013-03-14 2016-01-07 Uab Research Foundation Apolipoprotein mimetics and uses thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
PT3087183T (pt) 2013-12-24 2020-10-08 Ionis Pharmaceuticals Inc Modulação da expressão da proteína relacionada com angiopoietina 3
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
CA2955304C (en) 2014-07-16 2023-12-12 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
EP3201225B1 (en) 2014-10-03 2020-08-19 NGM Biopharmaceuticals, Inc. Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
MA44234B1 (fr) 2016-02-17 2023-10-31 Regeneron Pharma Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
RS62769B1 (sr) 2016-04-08 2022-01-31 Regeneron Pharma Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3
FI3448426T3 (fi) 2016-04-28 2025-07-18 Regeneron Pharma Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CA3188213A1 (en) 2020-08-07 2022-02-10 Robert C. Pordy Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor

Also Published As

Publication number Publication date
CN114007647A (zh) 2022-02-01
WO2020243031A1 (en) 2020-12-03
EA202193240A1 (ru) 2022-03-14
CL2021003026A1 (es) 2022-06-24
KR20220011727A (ko) 2022-01-28
IL288153A (en) 2022-01-01
CO2021016183A2 (es) 2021-12-10
AU2020282956A1 (en) 2022-01-27
US20200369760A1 (en) 2020-11-26
EP3976647A1 (en) 2022-04-06
MA56049A (fr) 2022-04-06
BR112021023501A2 (pt) 2022-01-18
JP7783051B2 (ja) 2025-12-09
CA3139333A1 (en) 2020-12-03
SG11202112256SA (en) 2021-12-30
JP2022532927A (ja) 2022-07-20
MX2021014332A (es) 2022-04-06
US12559551B2 (en) 2026-02-24

Similar Documents

Publication Publication Date Title
PH12021552788A1 (en) Stabilized formulations containing anti-angptl3 antibodies
PE20050394A1 (es) FORMULACIONES DE ANTICUERPO MONOCLONAL anti-lge ALTAMENTE CONCENTRADO
UY32609A (es) Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteína
CY1118373T1 (el) Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος
JP2023011641A (ja) 即効型インスリン組成物
AR109494A1 (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
EP4233892A3 (en) Stable anti-ifnar1 formulation
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
MY193913A (en) Stable Protein Solution Formulation Containing High Concentration of an Anti-Vegf Antibody
TN2009000382A1 (en) Stable antibody formulations
PE20050438A1 (es) Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
CN109789088A (zh) 新制剂
JOP20210152A1 (ar) صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf
JP2016514132A5 (https=)
JP2016539921A (ja) インスリングルリジンの安定製剤
FI3672631T3 (fi) Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia
DE60333821D1 (de) Stabilisierte albumin-zubereitungen
JP2020531523A5 (https=)
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
WO2021121444A3 (es) Formulación estable y de alta concentración del anticuerpo nimotuzumab
TW202611070A (zh) 用於抗N3pGlu類澱粉β抗體之調配物
MX2025009448A (es) Composiciones proteicas estables del anticuerpo anti-pd1
MX2024006318A (es) Formulacion para administracion de alta concentracion de proteina de fusion de hormona del crecimiento.
NZ747504B2 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
CN1897929A (zh) 包含5－甲基－2－(2′－氯－6′－氟苯胺基)苯乙酸的药物组合物